Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women

Kazuko Sugiura, Takao Kobayashi, Toshiyuki Ojima
Thrombosis research · 2015 · vol. 137 , pp. 11–16 · doi:10.1016/j.thromres.2015.11.038 · PMID:26672897 · W2186710508
Observational OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

This study investigated the relationship between body mass index, aging, and the risk of thromboembolism in Japanese women using hormonal contraceptives.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: The aim of this study is to estimate the risk of thromboembolism related to body mass index (BMI) and aging among users of hormonal contraceptives in Japan. METHODS: A case-control study of the risk of obesity and a descriptive study of the risk of age were conducted. We used the Pharmaceuticals and Medical Devices Agency database, and extracted thromboembolic events of combined oral contraceptive (COC) products. Control data were from the National Health and Nutrition Survey in Japan. Denominator of descriptive study was from IMS Health, JPM. RESULTS: A total of 306 thromboembolic events and 6423 controls were analyzed. The odds ratios (95% confidence interval) of the obesity groups (BMI ≥ 25) were 2.32 (1.71-3.15) for venous thromboembolism (VTE), 1.16 (0.62-2.18) for arterial embolism and thrombosis (ATE), and 1.83 (1.38-2.43) for overall thromboembolic events compared with the standard group (BMI of 18.5-24.9) as a reference. The estimated incidence rates of VTE, ATE and overall thromboembolic events per 10,000 person-years in users of therapeutic remedies for dysmenorrhea (35 μg ethinylestradiol combined with norethisterone, 20 μg ethinylestradiol combined with drospirenone and dienogest) among women aged 10-59 years from 2009 to 2013 were 2.38 (2.08-2.74), 0.63 (0.48-0.82), and 3.17 (2.81-3.57), respectively. This tendency was not seen for dienogest. CONCLUSIONS: The risk of VTE in the obesity group among COC users was more than 2 times higher than in the standard group. The incidence rates of VTE in Japanese users of all remedies for dysmenorrhea except dienogest were as high as in people in Western countries.

My notes (saved in your browser only)

MeSH descriptors

Body Mass Index Contraception Contraceptives, Oral, Hormonal Obesity Venous Thromboembolism Women's Health Adolescent Adult Aged Aged, 80 and over Age Distribution Case-Control Studies Child Comorbidity Contraception Contraceptives, Oral, Hormonal Contraceptives, Oral, Hormonal Female Humans Incidence

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (43)

Cited by (6)

Source provenance

openalex
last seen: 2026-05-11T05:58:56.137231+00:00
pubmed
last seen: 2026-10-08T21:16:59.636582+00:00
unpaywall
last seen: 2026-10-13T06:25:51.201866+00:00
License: CC0 · commercial use OK